Maloney KW, Devidas M, Wang C, et al. - In Children’s Oncology Group (COG) AALL0331, researchers examined the efficacy of intensified postinduction therapy, that improves survival in children with high-risk B-cell acute lymphoblastic leukemia (ALL), in improving outcomes for those with standard-risk (SR) ALL. Between 2005 and 2010, 5,377 patients were enrolled and were provided with a 3-drug induction with dexamethasone, vincristine, and pegaspargase (PEG). Then following classification of the patients was done: SR low, SR average, or SR high. They randomly assigned patients with SR-average disease to receive either standard 4-week consolidation or 8-week intensified augmented Berlin-Frankfurt-Münster consolidation (IC). Outcomes revealed the 6-year overall survival (OS) rate exceeding 95% for these children. No improvement in continuous complete remission or OS was noted in correlation to the addition of IC to treatment for patients with SR-average disease, even in patients with higher minimal residual disease, in whom it might have been predicted to provide more value. This group of patients with SR ALL had excellent event-free survival and OS rates, with particularly good outcomes in those with SR-high disease.